Biological Activity:

SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with IC50 0.071 μM. It stabilizes SHP2 in an auto-inhibited conformation, concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signaling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models. SHP099’s activity provides evidence that pharmacological inhibition of SHP2 is a viable strategy to target RTK-driven cancers and presents a new chemical tool for further interrogation of the multifaceted cellular functions of SHP2 in development, tumorigenesis, RTK-driven drug resistance and immune-checkpoint modulation.

How to Use:

In vitro: SHP099 was used at 10 µM in vitro and cellular assays.
In vivo: SHP099 was dosed orally to mouse tumor xenograft models at 75-100 mg/Kg once per day.

Reference:

• 1. Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. (2016) Nature. 535(7610):148-52.